# Best of UEG Week - HPB with Carolin Schneider

Page: https://stenobird.com/podcast/ueg-podcast-6404464/best-of-ueg-week-hpb-with-carolin-schneider
Text version: https://stenobird.com/podcast/ueg-podcast-6404464/best-of-ueg-week-hpb-with-carolin-schneider.md
Podcast: [UEG Podcast](https://stenobird.com/podcast/ueg-podcast-6404464)
Published: 2025-11-11T23:05:00+00:00
Episode link: https://ueg-talks-podcast.podigee.io/62-new-episode
Audio file: https://audio.podigee-cdn.net/2202695-m-7c25a79f4cfa5ca2741d76e8e356545f.mp3?source=feed
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/best-of-ueg-week-hpb-with-carolin-schneider
Duration seconds: 847

## Resource

In this episode, UEG's new Scientific Committee chair Jörn Schattenberg and Carolin Schneider, UEG rising start of 2025, recap the standout science from UEG Week 2025 in Berlin. They discuss highlights from the HPB field, including pivotal phase III data on linerixibat for cholestatic pruritus in PBC, advances in MASLD/MASH therapies such as FGF21 analogues and resmetirom, and new insights into liquid biopsy and AI-assisted imaging for pancreatic lesions. The conversation also explores simvastatin’s potential in preventing recurrent pancreatitis and reflects on the value of collaboration, precision medicine, and prospective clinical trials showcased at UEG Week.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/best-of-ueg-week-hpb-with-carolin-schneider/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ueg-podcast-6404464/best-of-ueg-week-hpb-with-carolin-schneider.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.